Send to

Choose Destination
Haemophilia. 2004 May;10(3):295-8.

Recombinant factor VIIa prophylaxis in a patient with severe congenital factor VII deficiency.

Author information

Childrens Hospital Los Angeles, Department of Hematology-Oncology, Los Angeles, CA, USA.


Use of recombinant factor VIIa (rFVIIa, NovoSeven in patients with congenital FVII deficiency has been reported for the prophylactic management of surgical bleeding and for the treatment of acute bleeding episodes. Because of its short half-life, the use of rFVIIa on a regular prophylactic regimen has not been routinely adopted. In this report, we describe our successful experience with rFVIIa prophylaxis in preventing recurrent target joint bleeding in a severely FVII-deficient adolescent.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center